Tuberculosis
Conditions
Keywords
Tuberculosis vaccine
Brief summary
The purpose of the study is to assess the safety and immunogenicity of a GlaxoSmithKline (GSK) Biologicals' candidate tuberculosis vaccine (692342) administered to Human Immunodeficiency Virus (HIV)-positive adults aged 18 to 59 years, living in a tuberculosis endemic region. Subjects will be followed-up for 3 years. Subjects will be enrolled in 3 cohorts: * HIV-positive adults on highly active antiretroviral therapy * HIV-positive adults not on highly active antiretroviral therapy * HIV-negative adults Each cohort will have 2 groups.
Detailed description
This Protocol Posting has been updated following Protocol Amendment 1, February 2011, leading to the update of the outcome measures and the inclusion and exclusion criteria.
Interventions
BIOLOGICALGSK's investigational vaccine 692342
Intramuscular, 2 doses
BIOLOGICALPhysiological saline
Intramuscular, 2 doses
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 59 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects who the investigator believes that they can and will comply with the requirements of the protocol. * A male or female between, and including, 18 and 59 years of age at the time of the first vaccination. * Written informed consent obtained from the subject prior to any study procedure. * Female subjects of non-childbearing potential may be enrolled in the study. * Female subjects of childbearing potential may be enrolled in the study, if the subject: * has practiced adequate contraception for 30 days prior to vaccination, * has a negative pregnancy test on the day of vaccination, and * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series. * Clinically acceptable laboratory values at screening as determined by the investigator. * No evidence of tuberculosis disease with no evidence of pulmonary pathology as confirmed by chest X-ray. * No history of extra pulmonary tuberculosis. * Based on their medical history, all subjects must have no history of chemotherapy for tuberculosis. Additional inclusion criteria for subjects to be enrolled in HIV+ on highly active antiretroviral therapy cohort: * Subjects must be HIV-positive and under care of a physician for at least 6 months. * Subjects must have a CD4+T cell count \>= 250 cells/mm3 at screening. * Subjects must be stable on highly active antiretroviral therapy for at least 6 months, with an undetectable HIV viral load level at screening. Additional inclusion criteria for subjects to be enrolled in HIV+ treatment naïve cohort: * Subjects must be HIV-positive and under care of a physician for at least 6 months * Subjects must be highly active antiretroviral therapy-naïve (never received anti-retroviral therapy after HIV diagnosis) * Subjects must have a CD4 + T cell count above 350 cells/mm3 at screening. * Subjects for whom commencement of highly active antiretroviral therapy is not expected based on current assessment within next year. * Subjects must have a viral load between 5000 - 80000 copies/mL at screening. Additional inclusion criteria for subjects to be enrolled in HIV-negative cohort • Subjects must be negative for HIV-1.
Exclusion criteria
* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Administration of a registered live vaccine not foreseen by the study within 30 days preceding the first dose of study vaccine and administration of a registered inactivated vaccine within 14 days preceding the first dose of study vaccine. * History of previous administration of experimental Mtb vaccines. * History of previous exposure to components of the investigational vaccine within 30 days preceding the first dose of study vaccine * Chronic administration of immunosuppressant or other immune-modifying drugs within six months prior to the first vaccine/product dose. For corticosteroids, this will mean prednisone \>= 20 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed. * Any condition or illness or medication, which in the opinion of the Investigator might interfere with the evaluation of the safety or immunogenicity of the vaccine. * Planned participation or participation in another experimental protocol with an experimental product during the study period. * Administration of any immunoglobulin, any immunotherapy and/or any blood products within the three months preceding the first dose of study vaccination, or planned administrations during the study period. * Subjects taking any of the following medication: chronic administration of systemic steroids, interleukins, systemic interferon or systemic chemotherapy. * History of allergic reactions or anaphylaxis to any drug or vaccine. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * History of chronic alcohol consumption and/or drug abuse which in the Investigator's opinion would put the subject at risk. * Pregnant female, lactating female or female planning to become pregnant or stop contraception. * Acute or chronic clinically relevant pulmonary, cardiovascular, hepatic or renal function abnormality as determined by physical examination or laboratory screening tests. Additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects With Grade 3 Solicited Local Symptoms | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses | Solicited local symptoms assessed were pain and swelling. Grade 3 pain = pain that prevented normal activity. Grade 3 swelling = swelling spreading beyond 50 millimeters (mm) of injection site. |
| Number of Subjects With Grade 3 Solicited General Symptoms | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses | Solicited general symptoms assessed were fatigue, temperature \[defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], gastrointestinal symptoms (gastro) \[nausea, vomiting, diarrhoea and/or abdominal pain\], headache, malaise and myalgia. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.5 °C. |
| Number of Subjects With Grade 3 Unsolicited Adverse Events (AEs) | During the 30-day (Days 0-29) post-vaccination period | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset out-side the specified period of follow-up for solicited symptoms. Grade 3 AE = an AE which prevented normal, everyday activities. |
| Number of Subjects With Serious Adverse Events (SAEs) | From screening up to one month post Dose 2 | Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. |
| Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | At Day 0 | Haematological and biochemical parameters assessed were haemoglobin \[Hgb\], white blood cells \[WBC\], platelets \[PLA\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and creatinine \[CREA\]. The haematology and biochemistry toxicity grading scale was based on the Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. |
| Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | At Day 7 | Haematological and biochemical parameters assessed were haemoglobin \[Hgb\], white blood cells \[WBC\], platelets \[PLA\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and creatinine \[CREA\]. The haematology and biochemistry toxicity grading scale was based on the Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. |
| Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | At Day 30 | Haematological and biochemical parameters assessed were haemoglobin \[Hgb\], white blood cells \[WBC\], platelets \[PLA\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and creatinine \[CREA\]. The haematology and biochemistry toxicity grading scale was based on the Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. |
| Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | At Day 37 | Haematological and biochemical parameters assessed were haemoglobin \[Hgb\], white blood cells \[WBC\], platelets \[PLA\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and creatinine \[CREA\]. The haematology and biochemistry toxicity grading scale was based on the Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. |
| Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | At Day 60 | Haematological and biochemical parameters assessed were haemoglobin \[Hgb\], white blood cells \[WBC\], platelets \[PLA\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and creatinine \[CREA\]. The haematology and biochemistry toxicity grading scale was based on the Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3 | Among cytokines expressed after background reduction were cluster of differentiation 40-ligand (CD40-L) interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). This endpoint presents results for the following cytokine combination: CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-),CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-),CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+). |
| Number of Subjects With Any Solicited Local Symptoms | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses | Solicited local symptoms assessed were pain and swelling. Any = occurrence of the symptom regardless of intensity grade. |
| Number of Subjects With Any Solicited General Symptoms | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses | Solicited general symptoms assessed were fatigue, gastrointestinal symptoms (Gastro), headache, malaise, myalgia and temperature. Any = occurrence of the symptom regardless of intensity grade. |
| Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | At Days 0, 30, 60, 210 and at Years 1, 2 and 3 | Concentration of M72-specific antibodies, as measured by the enzyme-linked immunosorbent assay (ELISA), were given in ELISA units per milliliter (EU/mL) and expressed as geometric mean concentrations (GMCs). |
| Number of Subjects With SAEs | From one month post Dose 2 up to study end (Year 3) | Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. |
| Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | At Days 0, 7, 30, 37 and 60 | Biochemical and haematological parameters included haemoglobin \[Hgb\], white blood cells \[WBC\], platelets \[PLA\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and creatinine \[CREA\]. Levels assessed were - normal, grade 1, grade 2 and missing grade. The haematology and biochemistry toxicity grading scale was based on the Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. |
| Number of Subjects With Any Unsolicited AEs | During the 30-day (Days 0-29) post-vaccination period | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. |
| Number of Seroconverted Subjects for M72-specific Antibodies | At Days 0, 30, 60, 210 and at Years 1, 2 and 3 | A seroconverted subject for M72 antibodies was defined as a seronegative subject at baseline, with the appearance of M72 antibody concentration higher than or equal to (≥) the cut-off value of 2.8 EL.U/mL post vaccination. Antibody concentrations below the cut-off value of the assay were given an arbitrary value of half the cut-off value for the purpose of GMC calculation. |
| Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3 | Among immune markers expressed after background reduction were interleukin-2 (IL-2), interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α) and cluster of differentiation 40 - ligand (CD40-L). This endpoint presents results for CD4-all doubles. |
| Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3 | Among cytokines expressed after background reduction were cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). This endpoint presents results for the following cytokine combinations: CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-),CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+),CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-),CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+). |
| M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3 | Among cytokines expressed after background reduction were cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). This endpoint presents results for the following cytokine combination: CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+),CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+),CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-) |
| M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3 | Among cytokines expressed after background reduction were cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). This endpoint presents results for the following cytokine combination: CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-),CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+),CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+). |
| Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3 | Among immune markers expressed after background reduction were interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). This endpoint presents results for CD8-all doubles. |
| Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3 | Among cytokines expressed after background reduction were cluster of differentiation 40-ligand (CD40-L) interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). This endpoint presents results for the following cytokine combination: CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+),CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-),CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+),CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-),CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+). |
| M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3 | Among cytokines expressed after background reduction were cluster of differentiation 40-ligand (CD40-L) interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). This endpoint presents results for the following cytokine combination: CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-),CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+),CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+),CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-). |
Countries
India
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| HIV(+)-HA/GSK692342 HIV-infected subjects between and including 18 to 59 years of age, who were on Highly Active Anti-Retroviral Therapy (HAART) at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region. | 40 |
| HIV(+)HA-/Placebo HIV-infected subjects between and including 18 to 59 years of age, who were on Highly Active Anti-Retroviral Therapy (HAART) at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region. | 40 |
| HIV(+)-TN/GSK692342 HIV-infected subjects between and including 18 to 59 years of age, who were HAART-treatment naive (TN) at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region. | 40 |
| HIV(+)-TN/Placebo HIV-infected subjects between and including 18 to 59 years of age, who were HAART-treatment naive (TN) at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region. | 40 |
| HIV(-)/GSK692342 Subjects between and including 18 to 59 years of age, who were HIV-negative at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region. | 40 |
| HIV(-)/Placebo Subjects between and including 18 to 59 years of age, who were HIV-negative at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region. | 40 |
| Total | 240 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Up to Month 2 | Lost to Follow-up | 1 | 0 | 0 | 1 | 1 | 1 |
| Up to Month 2 | Migrated/moved from study area | 0 | 1 | 0 | 0 | 1 | 1 |
| Up to Month 2 | Other | 1 | 0 | 0 | 1 | 0 | 2 |
| Up to Month 2 | Serious Adverse Event | 0 | 0 | 1 | 0 | 0 | 0 |
| Up to Month 2 | Withdrawal by Subject | 1 | 0 | 0 | 0 | 0 | 0 |
| Up to Month 7 | Lost to Follow-up | 1 | 0 | 1 | 3 | 1 | 3 |
| Up to Month 7 | Migrated/moved from study area | 0 | 0 | 1 | 3 | 1 | 1 |
| Up to Month 7 | Other | 3 | 0 | 2 | 0 | 0 | 0 |
| Up to Month 7 | Serious Adverse Event | 0 | 0 | 2 | 0 | 0 | 0 |
| Up to Month 7 | Withdrawal by Subject | 1 | 0 | 0 | 0 | 0 | 0 |
| Up to Year 1 | Lost to Follow-up | 4 | 0 | 0 | 1 | 6 | 5 |
| Up to Year 1 | Migrated/moved from study area | 1 | 0 | 0 | 3 | 3 | 2 |
| Up to Year 1 | Other | 3 | 1 | 0 | 0 | 2 | 1 |
| Up to Year 1 | Serious Adverse Event | 0 | 0 | 2 | 0 | 0 | 0 |
| Up to Year 1 | Subjects with unknown completion status | 0 | 0 | 1 | 0 | 0 | 1 |
| Up to Year 1 | Withdrawal by Subject | 1 | 0 | 0 | 0 | 0 | 0 |
| Up to Year 2 | Lost to Follow-up | 1 | 1 | 2 | 2 | 3 | 3 |
| Up to Year 2 | Migrated/moved from study area | 0 | 0 | 0 | 2 | 1 | 2 |
| Up to Year 2 | Other | 3 | 0 | 0 | 0 | 0 | 0 |
| Up to Year 2 | Serious Adverse Event | 0 | 0 | 2 | 0 | 0 | 0 |
| Up to Year 2 | Subjects with unknown completion status | 0 | 0 | 1 | 0 | 0 | 0 |
| Up to Year 2 | Withdrawal by Subject | 1 | 0 | 0 | 0 | 0 | 0 |
| Up to Year 3 | Lost to Follow-up | 2 | 2 | 4 | 3 | 1 | 3 |
| Up to Year 3 | Migrated/moved from study area | 0 | 0 | 0 | 2 | 1 | 1 |
| Up to Year 3 | Other | 3 | 0 | 0 | 0 | 0 | 0 |
| Up to Year 3 | Serious Adverse Event | 0 | 0 | 2 | 0 | 0 | 0 |
| Up to Year 3 | Subjects with unknown completion status | 0 | 0 | 1 | 0 | 0 | 0 |
| Up to Year 3 | Withdrawal by Subject | 1 | 0 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | HIV(+)-HA/GSK692342 | HIV(+)HA-/Placebo | HIV(+)-TN/GSK692342 | HIV(+)-TN/Placebo | HIV(-)/GSK692342 | HIV(-)/Placebo | Total |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 36.0 Years STANDARD_DEVIATION 6.5 | 35.5 Years STANDARD_DEVIATION 6.2 | 32.6 Years STANDARD_DEVIATION 6.5 | 32.2 Years STANDARD_DEVIATION 5.3 | 33.9 Years STANDARD_DEVIATION 7.6 | 34.6 Years STANDARD_DEVIATION 6.4 | 34.1 Years STANDARD_DEVIATION 6.5 |
| Race/Ethnicity, Customized Geographic ancestry Asian - Central/South Asian Heritage | 40 Participants | 40 Participants | 38 Participants | 36 Participants | 38 Participants | 39 Participants | 231 Participants |
| Race/Ethnicity, Customized Geographic ancestry Asian - East Asian Heritage | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Geographic ancestry Asian - South East Asian Heritage | 0 Participants | 0 Participants | 2 Participants | 3 Participants | 2 Participants | 1 Participants | 8 Participants |
| Sex: Female, Male Female | 27 Participants | 26 Participants | 29 Participants | 28 Participants | 30 Participants | 27 Participants | 167 Participants |
| Sex: Female, Male Male | 13 Participants | 14 Participants | 11 Participants | 12 Participants | 10 Participants | 13 Participants | 73 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 40 | 0 / 40 | 2 / 40 | 0 / 40 | 0 / 440 | 0 / 40 |
| other Total, other adverse events | 29 / 40 | 29 / 40 | 33 / 40 | 33 / 40 | 19 / 40 | 13 / 40 |
| serious Total, serious adverse events | 2 / 40 | 0 / 40 | 3 / 40 | 0 / 40 | 0 / 40 | 0 / 40 |
Outcome results
Primary
Number of Subjects With Grade 3-4 Haematological and Biochemical Levels
Haematological and biochemical parameters assessed were haemoglobin \[Hgb\], white blood cells \[WBC\], platelets \[PLA\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and creatinine \[CREA\]. The haematology and biochemistry toxicity grading scale was based on the Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.
Time frame: At Day 37
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - Hgb (Decrease) | 2 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - Hgb (Decrease) | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - CREA | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - Hgb (Decrease) | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - PLA | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - Hgb (Decrease) | 2 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - Hgb (Decrease) | 2 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - Hgb (Decrease) | 2 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - Hgb (Decrease) | 1 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - Hgb (Decrease) | 1 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological and Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 1 Participants |
Primary
Number of Subjects With Grade 3-4 Haematological/Biochemical Levels
Haematological and biochemical parameters assessed were haemoglobin \[Hgb\], white blood cells \[WBC\], platelets \[PLA\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and creatinine \[CREA\]. The haematology and biochemistry toxicity grading scale was based on the Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.
Time frame: At Day 60
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - AST | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - CREA | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - ALT | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - Hgb (Decrease) | 2 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - Hgb (Decrease) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - Hgb (Decrease) | 3 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - PLA | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - Hgb (Decrease) | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - Hgb (Decrease) | 2 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - Hgb (Decrease) | 1 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - Hgb (Decrease) | 1 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3-4 Haematological/Biochemical Levels | Grade 4 - PLA | 0 Participants |
Primary
Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels
Haematological and biochemical parameters assessed were haemoglobin \[Hgb\], white blood cells \[WBC\], platelets \[PLA\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and creatinine \[CREA\]. The haematology and biochemistry toxicity grading scale was based on the Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.
Time frame: At Day 7
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Decrease) | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Decrease) | 2 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - CREA | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - PLA | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Decrease) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Decrease) | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - PLA | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Decrease) | 2 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Decrease) | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Decrease) | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Decrease) | 3 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Decrease) | 2 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 1 Participants |
Primary
Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels
Haematological and biochemical parameters assessed were haemoglobin \[Hgb\], white blood cells \[WBC\], platelets \[PLA\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and creatinine \[CREA\]. The haematology and biochemistry toxicity grading scale was based on the Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.
Time frame: At Day 0
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Decrease) | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Decrease) | 2 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - CREA | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - PLA | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Decrease) | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Decrease) | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - PLA | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Decrease) | 2 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Decrease) | 3 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Decrease) | 2 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Decrease) | 2 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
Primary
Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels
Haematological and biochemical parameters assessed were haemoglobin \[Hgb\], white blood cells \[WBC\], platelets \[PLA\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and creatinine \[CREA\]. The haematology and biochemistry toxicity grading scale was based on the Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.
Time frame: At Day 30
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - Hgb (Decrease) | 2 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - Hgb (Decrease) | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - WBC (Increase) | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - CREA | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - Hgb (Decrease) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - PLA | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - Hgb (Decrease) | 3 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - Hgb (Decrease) | 2 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - Hgb (Decrease) | 1 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - WBC (Decrease) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - PLA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - CREA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - WBC (Increase) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - AST | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - PLA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - CREA | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - ALT | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - ALT | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - Hgb (Decrease) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - Hgb (Change from baseline) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - AST | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - Hgb (Decrease) | 2 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 4 - WBC (Increase) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - WBC (Decrease) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels | Grade 3 - Hgb (Change from baseline) | 1 Participants |
Primary
Number of Subjects With Grade 3 Solicited General Symptoms
Solicited general symptoms assessed were fatigue, temperature \[defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], gastrointestinal symptoms (gastro) \[nausea, vomiting, diarrhoea and/or abdominal pain\], headache, malaise and myalgia. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.5 °C.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available and who had filled in the symptom sheet.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Malaise, Dose 1 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Myalgia, Across doses | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Malaise, Across doses | 2 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Headache, Across doses | 2 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Gastro, Dose 1 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Gastro, Across doses | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Fatigue, Across doses | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Malaise, Dose 2 | 2 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Headache, Dose 2 | 2 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Gastro, Dose 2 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Headache, Dose 1 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Gastro, Dose 1 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Malaise, Dose 1 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Gastro, Dose 2 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Malaise, Dose 2 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Fatigue, Across doses | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Gastro, Across doses | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Headache, Across doses | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Malaise, Across doses | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Myalgia, Across doses | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Malaise, Dose 1 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Malaise, Dose 2 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Malaise, Across doses | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Gastro, Dose 2 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Headache, Across doses | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Gastro, Across doses | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Myalgia, Across doses | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Headache, Dose 2 | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Gastro, Dose 1 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Fatigue, Across doses | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Gastro, Dose 2 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Myalgia, Across doses | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Malaise, Dose 2 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Gastro, Dose 1 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Fatigue, Across doses | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Gastro, Across doses | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Headache, Across doses | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Malaise, Across doses | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Malaise, Dose 1 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Malaise, Dose 2 | 1 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 1 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Fatigue, Across doses | 1 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Headache, Dose 2 | 4 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Gastro, Across doses | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Gastro, Dose 2 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Headache, Across doses | 5 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 1 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 1 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Malaise, Dose 1 | 1 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Myalgia, Across doses | 1 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Malaise, Across doses | 1 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 1 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Gastro, Dose 1 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Headache, Dose 1 | 3 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Gastro, Dose 1 | 1 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Malaise, Across doses | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Myalgia, Across doses | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Malaise, Dose 2 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Fatigue, Across doses | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Gastro, Dose 2 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Malaise, Dose 1 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Gastro, Across doses | 1 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited General Symptoms | Grade 3 Headache, Across doses | 0 Participants |
Primary
Number of Subjects With Grade 3 Solicited Local Symptoms
Solicited local symptoms assessed were pain and swelling. Grade 3 pain = pain that prevented normal activity. Grade 3 swelling = swelling spreading beyond 50 millimeters (mm) of injection site.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available and who had filled in the symptom sheet.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 3 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 3 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 3 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 2 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 2 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 4 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 4 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
Primary
Number of Subjects With Grade 3 Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset out-side the specified period of follow-up for solicited symptoms. Grade 3 AE = an AE which prevented normal, everyday activities.
Time frame: During the 30-day (Days 0-29) post-vaccination period
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HIV(+)-HA/GSK692342 | Number of Subjects With Grade 3 Unsolicited Adverse Events (AEs) | 26 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Grade 3 Unsolicited Adverse Events (AEs) | 27 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Grade 3 Unsolicited Adverse Events (AEs) | 35 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Grade 3 Unsolicited Adverse Events (AEs) | 33 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Grade 3 Unsolicited Adverse Events (AEs) | 13 Participants |
| HIV(-)/Placebo | Number of Subjects With Grade 3 Unsolicited Adverse Events (AEs) | 13 Participants |
Primary
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From screening up to one month post Dose 2
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HIV(+)-HA/GSK692342 | Number of Subjects With Serious Adverse Events (SAEs) | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Serious Adverse Events (SAEs) | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Serious Adverse Events (SAEs) | 2 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Serious Adverse Events (SAEs) | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Serious Adverse Events (SAEs) | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Serious Adverse Events (SAEs) | 0 Participants |
Secondary
Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations
Concentration of M72-specific antibodies, as measured by the enzyme-linked immunosorbent assay (ELISA), were given in ELISA units per milliliter (EU/mL) and expressed as geometric mean concentrations (GMCs).
Time frame: At Days 0, 30, 60, 210 and at Years 1, 2 and 3
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 210 | 45.5 EU/mL |
| HIV(+)-HA/GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Year 3 | 22.0 EU/mL |
| HIV(+)-HA/GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 0 | 1.4 EU/mL |
| HIV(+)-HA/GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Year 1 | 28.0 EU/mL |
| HIV(+)-HA/GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Year 2 | 19.1 EU/mL |
| HIV(+)-HA/GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 60 | 469.3 EU/mL |
| HIV(+)-HA/GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 30 | 4.9 EU/mL |
| HIV(+)-HA/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Year 3 | 1.4 EU/mL |
| HIV(+)-HA/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Year 1 | 1.4 EU/mL |
| HIV(+)-HA/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 30 | 1.4 EU/mL |
| HIV(+)-HA/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 60 | 1.5 EU/mL |
| HIV(+)-HA/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 0 | 1.4 EU/mL |
| HIV(+)-HA/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Year 2 | 1.4 EU/mL |
| HIV(+)-HA/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 210 | 1.4 EU/mL |
| HIV(+)-TN/ GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 60 | 249.4 EU/mL |
| HIV(+)-TN/ GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Year 1 | 9.3 EU/mL |
| HIV(+)-TN/ GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Year 2 | 5.4 EU/mL |
| HIV(+)-TN/ GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 0 | 1.5 EU/mL |
| HIV(+)-TN/ GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 30 | 6.0 EU/mL |
| HIV(+)-TN/ GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Year 3 | 4.9 EU/mL |
| HIV(+)-TN/ GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 210 | 17.7 EU/mL |
| HIV(+)-TN/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 210 | 1.4 EU/mL |
| HIV(+)-TN/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 0 | 1.4 EU/mL |
| HIV(+)-TN/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 30 | 1.4 EU/mL |
| HIV(+)-TN/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 60 | 1.4 EU/mL |
| HIV(+)-TN/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Year 1 | 1.4 EU/mL |
| HIV(+)-TN/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Year 2 | 1.4 EU/mL |
| HIV(+)-TN/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Year 3 | 1.4 EU/mL |
| HIV(-)/GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Year 1 | 29.4 EU/mL |
| HIV(-)/GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 60 | 754.5 EU/mL |
| HIV(-)/GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Year 2 | 23.9 EU/mL |
| HIV(-)/GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 30 | 11.2 EU/mL |
| HIV(-)/GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 0 | 1.4 EU/mL |
| HIV(-)/GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 210 | 58.3 EU/mL |
| HIV(-)/GSK692342 | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Year 3 | 24.3 EU/mL |
| HIV(-)/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 30 | 1.5 EU/mL |
| HIV(-)/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Year 1 | 1.5 EU/mL |
| HIV(-)/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 60 | 1.5 EU/mL |
| HIV(-)/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 210 | 1.5 EU/mL |
| HIV(-)/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Year 3 | 1.5 EU/mL |
| HIV(-)/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Day 0 | 1.5 EU/mL |
| HIV(-)/Placebo | Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations | Anti-M72, Year 2 | 1.5 EU/mL |
Secondary
Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines
Among cytokines expressed after background reduction were cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). This endpoint presents results for the following cytokine combinations: CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-),CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+),CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-),CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+).
Time frame: At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
Population: The analysis was performed on the ATP cohort for immunogenicity,which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 58.5 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 525.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 307.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 2229.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 1257.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 967.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 798.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 685.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 1078.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 9.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 110.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 450.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 1975.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 2162.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1370.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1536.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1130.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 1321.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+) IL2(+)+TNFa(-)+IFNg(+), Day 7 | 74.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 63.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 816.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 325.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 128.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 160.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 133.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 120.5 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 94.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 351.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 2065.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 1591.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 476.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 484.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 526.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 214.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 66.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 391.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 72.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 57.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 32.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 39.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 38.5 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 13.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 8.5 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 17.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 59.5 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 18.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 15.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 26.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 117.5 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 76.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 32.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 85.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 11.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 102.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 109.5 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 22.5 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 32.5 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 86.5 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 30.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 117.5 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 15.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.5 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 13.5 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 121.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+) IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 21.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 8.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 42.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 113.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 282.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 8.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 425.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+) IL2(+)+TNFa(-)+IFNg(+), Day 7 | 65.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 18.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 53.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 616.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 51.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 117.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 214.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 103.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 20.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 28.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 180.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 78.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 204.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 127.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 1290.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 103.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 158.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 671.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 155.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 140.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 165.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 20.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 788.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 28.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 18.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 507.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 305.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 380.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 220.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 28.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 4.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 32.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 16.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 18.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 32.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+) IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 19.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 23.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 19.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 24.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 30.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 29.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 145.5 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 546.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 1145.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 754.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 510.5 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 35.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 60.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 76.5 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 7.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 247.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+) IL2(+)+TNFa(-)+IFNg(+), Day 7 | 148.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 185.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 182.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 315.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 324.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 46.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 94.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 500.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 411.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 9.5 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 29.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 600.5 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 893.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 93.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 117.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 684.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 318.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 257.5 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 937.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 435.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 369.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 463.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 410.5 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 1639.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 31.5 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 60.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 57.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 51.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 58.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 119.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 101.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 77.5 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 234.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 88.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 128.5 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 9.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 14.5 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 54.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 57.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 105.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 5.5 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 14.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 15.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+) IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 14.5 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 125.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 13.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 32.5 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 139.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 2.5 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 14.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 27.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 5.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 57.5 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 18.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 27.5 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 1.5 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 106.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 19.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 18.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 15.0 T-cells/million cells |
Secondary
Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines
Among cytokines expressed after background reduction were cluster of differentiation 40-ligand (CD40-L) interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). This endpoint presents results for the following cytokine combination: CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+),CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-),CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+),CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-),CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+).
Time frame: At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 13.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 16.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+) IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 14.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+) IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 6.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+) IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 6.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 13.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+) IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 26.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+) IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+) IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
Secondary
Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers
Among immune markers expressed after background reduction were interleukin-2 (IL-2), interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α) and cluster of differentiation 40 - ligand (CD40-L). This endpoint presents results for CD4-all doubles.
Time frame: At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles,Year 2 | 2982.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles,Year 3 | 3533.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 30 | 1661.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 210 | 3488.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles,Year 1 | 3593.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 60 | 7505.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 7 | 1253.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 0 | 176.5 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 37 | 9060.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles,Year 3 | 320.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 210 | 346.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 7 | 278.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 30 | 306.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 0 | 279.5 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles,Year 2 | 281.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 37 | 210.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles,Year 1 | 373.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 60 | 230.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 7 | 693.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 210 | 1084.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 37 | 5346.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles,Year 2 | 449.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles,Year 3 | 491.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 30 | 610.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles,Year 1 | 863.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 60 | 2283.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 0 | 173.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 210 | 189.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 0 | 145.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 7 | 168.5 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 30 | 163.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 37 | 94.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 60 | 148.5 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles,Year 1 | 191.5 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles,Year 2 | 141.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles,Year 3 | 293.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 60 | 2913.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 37 | 5705.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles,Year 1 | 1181.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 30 | 1499.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles,Year 3 | 1617.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles,Year 2 | 1364.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 7 | 2352.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 0 | 216.5 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 210 | 1630.5 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 0 | 290.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 37 | 204.5 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 210 | 287.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles,Year 3 | 316.5 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles,Year 2 | 261.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles,Year 1 | 274.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 30 | 312.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 60 | 229.5 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers | CD4-all doubles, Day 7 | 274.0 T-cells/million cells |
Secondary
Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers
Among immune markers expressed after background reduction were interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). This endpoint presents results for CD8-all doubles.
Time frame: At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 7 | 224.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 30 | 90.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 210 | 82.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Year 3 | 127.5 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 0 | 71.5 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Year 2 | 65.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 60 | 118.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 37 | 168.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Year 1 | 52.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 30 | 85.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Year 3 | 41.5 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 60 | 72.5 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 210 | 28.5 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 37 | 45.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 7 | 107.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Year 1 | 49.0 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 0 | 68.5 T-cells/million cells |
| HIV(+)-HA/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Year 2 | 42.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 60 | 91.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Year 3 | 48.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Year 1 | 47.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 7 | 149.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 30 | 60.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 210 | 42.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 0 | 58.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Year 2 | 46.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 37 | 179.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Year 3 | 69.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 37 | 54.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 60 | 64.5 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 210 | 55.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Year 1 | 46.5 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Year 2 | 46.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 0 | 37.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 7 | 71.0 T-cells/million cells |
| HIV(+)-TN/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 30 | 62.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Year 2 | 40.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Year 1 | 52.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 0 | 65.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 210 | 53.5 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 30 | 56.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 7 | 158.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 60 | 55.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 37 | 157.0 T-cells/million cells |
| HIV(-)/GSK692342 | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Year 3 | 94.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 37 | 78.5 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Year 1 | 58.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Year 3 | 66.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 30 | 83.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 7 | 72.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 0 | 84.5 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 210 | 32.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Year 2 | 11.0 T-cells/million cells |
| HIV(-)/Placebo | Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers | CD8-all doubles, Day 60 | 135.0 T-cells/million cells |
Secondary
M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines
Among cytokines expressed after background reduction were cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). This endpoint presents results for the following cytokine combination: CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-),CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+),CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+).
Time frame: At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 46.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 21.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 17.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 64.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 59.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 14.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 14.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 29.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 85.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 18.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 15.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 8.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 5.5 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 120.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 32.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 10.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 45.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 8.5 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 23.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 61.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 61.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 135.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 2.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 27.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 16.5 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 9.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 2.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 21.5 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 51.5 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 11.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 2.5 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 17.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 20.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 28.5 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 18.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 118.5 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 13.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 30.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 11.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 16.5 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 18.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 40.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 80.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 12.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 13.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 7.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 19.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 6.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 25.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 28.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 260.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 18.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 2.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 82.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 31.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 74.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 7.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 18.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 25.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 3.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 18.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 15.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 44.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 17.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 9.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 7.5 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 49.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 18.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 3.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 30.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 45.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 62.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 39.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 16.5 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 40.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 56.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 7.5 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 1.5 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 93.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 22.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 245.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 7 | 16.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 17.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 60.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 21.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 37.5 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 20.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 35.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 36.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 320.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 2.5 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 14.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 68.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 36.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 3.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 34.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 29.5 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 48.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 16.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 12.5 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 25.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 11.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 25.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 62.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 6.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 14.5 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 14.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 34.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 16.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 12.5 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 18.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 23.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 2.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 7.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
Secondary
M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines
Among cytokines expressed after background reduction were cluster of differentiation 40-ligand (CD40-L) interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). This endpoint presents results for the following cytokine combination: CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-),CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-),CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+).
Time frame: At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 3.5 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 52.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 35.5 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 41.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 40.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 59.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 33.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 36.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 13.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 20.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 60.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 4.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 36.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 35.5 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 38.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 67.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 65.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 49.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 79.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 29.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 37.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 70.5 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 12.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 31.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 50.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 27.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 46.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 20.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 108.5 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 71.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 144.5 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 3.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 7.5 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 16.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 34.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 43.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 74.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 26.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 19.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 18.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 17.5 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 38.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 41.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 16.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 62.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 84.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 15.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 33.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 29.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 18.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 47.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 25.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 20.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 27.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 7.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 26.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 55.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 44.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 35.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 58.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 13.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 73.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 43.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 32.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 1.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 9.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 33.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 10.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 30.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 37.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 10.5 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 24.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 95.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 75.5 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 21.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 23.5 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 27.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 24.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 32.5 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 8.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 19.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 11.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 44.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 33.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 6.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 50.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 61.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 37.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 23.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 50.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 9.5 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 51.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 29.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 3.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 28.5 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 31.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 8.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 57.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 33.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 40.5 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 56.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 25.5 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 29.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 59.5 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 17.5 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 37 | 22.5 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 19.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 30 | 52.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 16.5 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 1.5 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 119.5 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 7 | 35.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 28.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 41.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 0 | 68.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 2 | 22.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 27.5 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 112.5 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 210 | 18.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 116.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 93.5 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 128.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 30 | 5.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 3.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 30.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 3 | 33.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), Day 60 | 72.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
Secondary
M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines
Among cytokines expressed after background reduction were cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). This endpoint presents results for the following cytokine combination: CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+),CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+),CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-)
Time frame: At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 48.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 54.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 583.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 274.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 48.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 61.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 84.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 78.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 117.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 21.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 725.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 74.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 26.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 15.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 14.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 12.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 37 | 1510.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Year 3 | 70.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 38.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 2.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 43.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 26.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 13.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 17.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 27.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 4.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 17.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 51.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 37 | 300.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 30.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 21.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 40.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 30.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 36.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 37.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 211.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 25.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 388.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 35.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 34.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 28.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 123.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 16.5 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 17.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 2.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 37 | 1400.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 24.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 55.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 19.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 85.5 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 34.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 1.5 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 740.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 40.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 81.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 15.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 15.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 22.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 43.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 399.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 97.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 72.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 13.5 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 84.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 110.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 19.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 29.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 26.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 7.5 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 3.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 1.5 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 8.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 4.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 10.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 13.5 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 14.5 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 8.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 31.5 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 13.5 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 7.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 7.5 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines | CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
Secondary
M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines
Among cytokines expressed after background reduction were cluster of differentiation 40-ligand (CD40-L) interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). This endpoint presents results for the following cytokine combination: CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-),CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+),CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+),CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-).
Time frame: At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
Population: The analysis was performed on the ATP cohort for immunogenicity,which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 210 | 20.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 7 | 72.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 2.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 37 | 146.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 37 | 110.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 60 | 4.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 210 | 4.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 0 | 64.5 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 7 | 25.0 T-cells/million cells |
| HIV(+)-HA/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 37 | 23.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 7 | 3.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 0 | 155.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 20.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/ GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 0 | 70.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 7 | 72.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 30 | 47.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 37 | 20.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 60 | 66.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),Year 1 | 33.5 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(+)-TN/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),Year 2 | 18.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 60 | 88.5 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 30 | 210.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 2.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 2.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 7 | 74.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 0 | 22.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/GSK692342 | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),Year 2 | 15.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 0 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 37 | 93.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 30 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 30 | 5.5 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-), Day 7 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 1 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 210 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 2 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 37 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 60 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Year 3 | 1.0 T-cells/million cells |
| HIV(-)/Placebo | M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines | CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-), Day 30 | 1.0 T-cells/million cells |
Secondary
Number of Seroconverted Subjects for M72-specific Antibodies
A seroconverted subject for M72 antibodies was defined as a seronegative subject at baseline, with the appearance of M72 antibody concentration higher than or equal to (≥) the cut-off value of 2.8 EL.U/mL post vaccination. Antibody concentrations below the cut-off value of the assay were given an arbitrary value of half the cut-off value for the purpose of GMC calculation.
Time frame: At Days 0, 30, 60, 210 and at Years 1, 2 and 3
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 0 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Year 1 | 30 Participants |
| HIV(+)-HA/GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 30 | 23 Participants |
| HIV(+)-HA/GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Year 3 | 33 Participants |
| HIV(+)-HA/GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 60 | 36 Participants |
| HIV(+)-HA/GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Year 2 | 33 Participants |
| HIV(+)-HA/GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 210 | 34 Participants |
| HIV(+)-HA/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 30 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 210 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 60 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Year 1 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 0 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Year 3 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Year 2 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 60 | 37 Participants |
| HIV(+)-TN/ GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 30 | 27 Participants |
| HIV(+)-TN/ GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 0 | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Year 1 | 29 Participants |
| HIV(+)-TN/ GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Year 2 | 24 Participants |
| HIV(+)-TN/ GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 210 | 29 Participants |
| HIV(+)-TN/ GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Year 3 | 22 Participants |
| HIV(+)-TN/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 210 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 0 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 30 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 60 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Year 1 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Year 2 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Year 3 | 0 Participants |
| HIV(-)/GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 60 | 36 Participants |
| HIV(-)/GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 30 | 35 Participants |
| HIV(-)/GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Year 3 | 36 Participants |
| HIV(-)/GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 0 | 0 Participants |
| HIV(-)/GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Year 2 | 34 Participants |
| HIV(-)/GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 210 | 36 Participants |
| HIV(-)/GSK692342 | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Year 1 | 27 Participants |
| HIV(-)/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Year 3 | 1 Participants |
| HIV(-)/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Year 1 | 1 Participants |
| HIV(-)/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 60 | 1 Participants |
| HIV(-)/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 30 | 1 Participants |
| HIV(-)/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Year 2 | 1 Participants |
| HIV(-)/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 0 | 2 Participants |
| HIV(-)/Placebo | Number of Seroconverted Subjects for M72-specific Antibodies | Anti-M72, Day 210 | 2 Participants |
Secondary
Number of Subjects Presenting Different Grades of Haematological and Biochemical Values
Biochemical and haematological parameters included haemoglobin \[Hgb\], white blood cells \[WBC\], platelets \[PLA\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and creatinine \[CREA\]. Levels assessed were - normal, grade 1, grade 2 and missing grade. The haematology and biochemistry toxicity grading scale was based on the Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.
Time frame: At Days 0, 7, 30, 37 and 60
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 37 | 38 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 60 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 7 | 27 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 7 | 6 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 7 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 37 | 9 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 7 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 60 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 30 | 9 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 60 | 30 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 7 | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 7 | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 60 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 0 | 39 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 7 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 7 | 9 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 7 | 39 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 30 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 0 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 0 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 60 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 30 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 7 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 0 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 30 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 0 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 37 | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 7 | 30 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 0 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 30 | 9 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 0 | 40 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 0 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 30 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 60 | 6 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 60 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 60 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 30 | 32 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 7 | 39 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 0 | 5 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 60 | 15 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 60 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 30 | 39 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 60 | 3 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 7 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 60 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 37 | 28 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 0 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 60 | 34 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 30 | 6 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 7 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 37 | 15 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 0 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 37 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 30 | 23 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 37 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 7 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 0 | 40 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 0 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 60 | 21 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 37 | 4 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 30 | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 30 | 38 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 30 | 17 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 30 | 30 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 37 | 34 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 60 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 30 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 30 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 37 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 60 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 60 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 30 | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 30 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 30 | 2 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 30 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 37 | 22 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 7 | 3 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 60 | 37 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 30 | 35 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 60 | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 30 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 7 | 20 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 30 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 7 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 37 | 29 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 7 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 37 | 37 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 37 | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 0 | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 7 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 7 | 2 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 60 | 36 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 37 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 0 | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 37 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 7 | 38 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 37 | 8 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 37 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 0 | 3 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 0 | 6 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 0 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 37 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 0 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 37 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 7 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 60 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 37 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 0 | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 0 | 6 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 60 | 36 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 37 | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA Day 37 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 0 | 39 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 30 | 21 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 60 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 60 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 37 | 3 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 0 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 37 | 35 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 60 | 2 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 37 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 60 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 7 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 60 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 60 | 9 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 37 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 60 | 24 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 60 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 30 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 0 | 33 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 7 | 7 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 37 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 60 | 28 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 0 | 19 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 37 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 7 | 33 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 37 | 4 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 30 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 37 | 9 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 0 | 21 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 0 | 28 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 0 | 34 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 30 | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 37 | 22 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 60 | 8 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 0 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 7 | 20 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 7 | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 30 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 30 | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 30 | 4 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 0 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 30 | 38 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 30 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 7 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 7 | 40 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 0 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 7 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 0 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 7 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 7 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 0 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 7 | 39 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 7 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 7 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 0 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 7 | 40 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 30 | 22 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 7 | 24 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 7 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 7 | 15 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 60 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 7 | 5 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 7 | 11 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 7 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 7 | 24 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 7 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 0 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 0 | 3 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 30 | 24 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 60 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 0 | 11 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 30 | 15 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 0 | 9 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 0 | 25 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 60 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 30 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 60 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 30 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 60 | 12 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 60 | 26 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 37 | 23 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 60 | 38 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 37 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 37 | 15 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 37 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 0 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 37 | 6 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA Day 37 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 37 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 0 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 30 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 37 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 7 | 30 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 30 | 6 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 37 | 38 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 30 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 7 | 10 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 7 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 30 | 34 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 30 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 7 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 30 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 30 | 40 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 30 | 33 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 37 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 0 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 30 | 7 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 60 | 32 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 0 | 39 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 60 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 30 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 60 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 30 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 7 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 60 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 60 | 38 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 37 | 32 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 37 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 37 | 7 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 37 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 37 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 37 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 37 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 37 | 38 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 37 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 37 | 33 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 30 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 30 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 60 | 31 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 7 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 30 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 60 | 7 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 30 | 39 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 7 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 60 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 7 | 7 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 7 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 60 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 7 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 7 | 40 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 0 | 40 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 0 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 0 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 7 | 32 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 0 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 0 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 0 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 0 | 39 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 0 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 60 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 60 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 30 | 15 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 60 | 7 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 60 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 7 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 60 | 38 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 37 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 7 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 0 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 37 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 7 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 37 | 3 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 37 | 36 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 30 | 40 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 0 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 30 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 30 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 30 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 30 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 30 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 60 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 30 | 40 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 7 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 30 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 7 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 37 | 39 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 7 | 2 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 7 | 38 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 37 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 0 | 6 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 0 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 37 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 0 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 37 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 0 | 3 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 0 | 37 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 60 | 39 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 60 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 60 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 60 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 30 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 60 | 4 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 60 | 10 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 60 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 0 | 34 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 60 | 25 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 60 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 37 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 37 | 2 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 0 | 28 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 60 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 37 | 12 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 0 | 11 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 37 | 24 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 30 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 0 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 0 | 31 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 30 | 3 Participants |
| HIV(+)-HA/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 0 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 30 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 37 | 37 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 37 | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 37 | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 37 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 60 | 5 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 60 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 60 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 0 | 35 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 0 | 5 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 0 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 0 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 7 | 32 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 7 | 7 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 7 | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 7 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 30 | 33 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 30 | 7 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 30 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 30 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 37 | 30 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 37 | 9 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 37 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 37 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 60 | 27 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 60 | 12 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 60 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 60 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 0 | 40 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 0 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 0 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 0 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 7 | 40 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 7 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 7 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 7 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 30 | 40 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 30 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 60 | 34 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 30 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 37 | 39 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 37 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 37 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 37 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 60 | 39 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 60 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 60 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 60 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 0 | 26 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 0 | 14 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 0 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 0 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 7 | 26 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 7 | 14 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 7 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 7 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 30 | 22 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 30 | 16 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 30 | 2 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 30 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 37 | 20 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 37 | 16 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 37 | 3 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 37 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 60 | 26 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 60 | 12 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 60 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 60 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 0 | 19 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 0 | 9 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 0 | 9 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 0 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 7 | 19 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 7 | 11 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 7 | 7 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 7 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 30 | 17 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 30 | 10 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 30 | 10 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 30 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 37 | 16 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 37 | 12 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 37 | 9 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 37 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 60 | 17 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 60 | 13 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 60 | 6 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 60 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 0 | 38 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 0 | 2 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 0 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 0 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 7 | 38 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 7 | 2 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 7 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 7 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 30 | 38 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 30 | 2 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 30 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 30 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 37 | 38 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 37 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 37 | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 37 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 60 | 37 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 60 | 2 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 60 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 60 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 0 | 40 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 0 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 0 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 0 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 7 | 40 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 7 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 7 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 7 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 30 | 40 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 30 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 30 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 30 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 37 | 39 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 37 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 37 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 37 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 60 | 39 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 60 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 60 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 60 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 0 | 38 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 0 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 30 | 39 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 30 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 30 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 30 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 37 | 38 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 37 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 37 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA Day 37 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 60 | 38 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 60 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 60 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 60 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 0 | 38 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 0 | 2 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 0 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 0 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 7 | 34 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 7 | 6 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 7 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 7 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 30 | 35 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 30 | 5 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 30 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 30 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 0 | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 7 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 0 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 7 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 7 | 39 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 7 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 0 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 7 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 0 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 7 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 7 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 7 | 39 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 37 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 7 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 0 | 40 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 7 | 13 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 37 | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 60 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 30 | 9 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 30 | 15 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 7 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 60 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 60 | 35 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 60 | 7 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 30 | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 60 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 37 | 17 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 7 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 60 | 3 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 60 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 60 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 7 | 39 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 7 | 9 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 30 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 60 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 60 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 30 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 60 | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 0 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 60 | 38 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 60 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 60 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 37 | 29 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 37 | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 7 | 7 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 7 | 34 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 0 | 40 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 60 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 37 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 0 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 37 | 11 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 60 | 38 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 0 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 60 | 10 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 37 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 7 | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 0 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 37 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 0 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 0 | 37 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 37 | 39 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 7 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 30 | 9 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 60 | 34 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 0 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 30 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 30 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 0 | 40 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 37 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 30 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 7 | 39 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 0 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 37 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 37 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 60 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 37 | 35 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 7 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 60 | 26 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 60 | 27 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 30 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 0 | 3 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 7 | 5 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 7 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 37 | 12 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 30 | 40 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 60 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 60 | 11 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 37 | 26 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 7 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 37 | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 7 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 0 | 5 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 0 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 7 | 21 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 0 | 10 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 37 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 37 | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 0 | 27 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 0 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 60 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 37 | 12 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 37 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 60 | 38 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 30 | 4 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 7 | 37 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 60 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA Day 37 | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 37 | 8 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 37 | 40 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 60 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 7 | 2 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 0 | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 0 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 37 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 0 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 37 | 5 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 7 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 0 | 30 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 0 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 30 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 37 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 30 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 7 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 60 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 37 | 39 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 30 | 22 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 30 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 0 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 30 | 40 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 37 | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 7 | 30 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 30 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 30 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 7 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 30 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 0 | 9 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 7 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 30 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 7 | 25 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 30 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 30 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 0 | 35 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 30 | 36 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 30 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 60 | 21 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 7 | 9 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 30 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 30 | 25 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 30 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 30 | 40 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 7 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 60 | 4 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 37 | 35 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 60 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 30 | 40 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 0 | 3 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 7 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 30 | 7 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 37 | 4 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 60 | 9 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 30 | 30 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 0 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 0 | 12 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 0 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 37 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 0 | 25 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 0 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 30 | 10 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 0 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 30 | 7 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 60 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 30 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 0 | 19 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 37 | 20 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 0 | 21 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 60 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 37 | 12 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 37 | 5 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 60 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 37 | 35 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 37 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 60 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 60 | 22 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 0 | 38 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 60 | 9 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 60 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 60 | 5 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 60 | 38 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 60 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 60 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 0 | 35 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 37 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 0 | 4 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 37 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 0 | 1 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 0 | 2 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 0 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 7 | 36 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 37 | 39 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 7 | 3 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 30 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 7 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 7 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 30 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 30 | 39 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 30 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 0 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 30 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 37 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 30 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 30 | 39 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 60 | 3 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 30 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 37 | 35 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 7 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 30 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 37 | 4 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 7 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 37 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 0 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 37 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 7 | 1 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 60 | 34 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 7 | 38 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 60 | 4 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 60 | 35 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 60 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 0 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 60 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 0 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 0 | 40 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 7 | 35 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 0 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 0 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 0 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 0 | 40 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 0 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 7 | 39 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 60 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 7 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 60 | 1 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 7 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 7 | 4 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 7 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 60 | 4 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 30 | 39 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 60 | 33 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 37 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 30 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 30 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 37 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 7 | 5 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 30 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 37 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 37 | 39 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 7 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 37 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 37 | 4 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 37 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 37 | 35 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 37 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 37 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 60 | 38 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 30 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 60 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 30 | 1 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 60 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 7 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 60 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 30 | 5 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 0 | 40 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 30 | 33 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 0 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 7 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 30 | 39 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 7 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 30 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 7 | 1 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 30 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 30 | 36 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 30 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 7 | 33 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 37 | 38 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 0 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 37 | 4 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 37 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 37 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 0 | 1 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 30 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA Day 37 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 0 | 2 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 60 | 38 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 37 | 21 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 37 | 1 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 37 | 17 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 37 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 60 | 19 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 30 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 30 | 3 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 60 | 19 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 30 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 60 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 60 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 60 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 30 | 19 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 0 | 23 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 30 | 20 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 0 | 10 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 0 | 37 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 0 | 5 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 7 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 0 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 7 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 7 | 22 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 60 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 7 | 9 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 7 | 22 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 7 | 5 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 7 | 17 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 7 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 30 | 21 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 7 | 39 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 0 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 0 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 7 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 7 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 0 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 7 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 7 | 40 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 0 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 0 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 7 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 30 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 0 | 40 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 30 | 35 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 0 | 22 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 37 | 1 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 7 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 30 | 23 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 30 | 12 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 7 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 37 | 4 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 7 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 37 | 2 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 37 | 32 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 0 | 38 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 30 | 38 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 60 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 7 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 30 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 30 | 38 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 7 | 5 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 30 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 7 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 0 | 13 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 30 | 2 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 0 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 60 | 21 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 30 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 30 | 2 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 7 | 36 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 7 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 30 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 7 | 21 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 30 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 60 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 30 | 34 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 30 | 35 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 7 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 37 | 35 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 37 | 37 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 0 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 0 | 3 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 0 | 17 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 30 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 37 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 37 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 7 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 0 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 60 | 2 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 30 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 30 | 3 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 37 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 37 | 4 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 7 | 3 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 30 | 2 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 7 | 37 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 0 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA Day 37 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 0 | 2 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 7 | 1 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 0 | 3 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 37 | 37 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 30 | 22 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 37 | 19 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 60 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 0 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - PLA, Day 60 | 35 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 37 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 37 | 10 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 37 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 37 | 17 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 7 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 0 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 37 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 7 | 22 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 37 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 0 | 4 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 30 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 7 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 7 | 4 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 60 | 5 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - ALT, Day 7 | 5 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 7 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 30 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 30 | 38 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 60 | 30 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 0 | 23 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Change from baseline), Day 60 | 18 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 60 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 7 | 17 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 30 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 7 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 37 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 7 | 40 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 37 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 0 | 36 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 30 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 0 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 60 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 37 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 0 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - Hgb (Decrease), Day 37 | 21 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 30 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 37 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 60 | 17 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 0 | 40 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 0 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 30 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 37 | 37 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 7 | 35 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 37 | 1 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 0 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 0 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Decrease), Day 60 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 37 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 60 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 0 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 7 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 0 | 40 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 7 | 11 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 37 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - AST, Day 37 | 36 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Change from baseline), Day 60 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 37 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - CREA, Day 0 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 60 | 35 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 37 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 60 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - AST, Day 30 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Change from baseline), Day 30 | 14 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - ALT, Day 30 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 60 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Decrease), Day 60 | 35 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - Hgb (Decrease), Day 60 | 2 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Increase), Day 60 | 1 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - CREA, Day 0 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Increase), Day 60 | 5 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - PLA, Day 60 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - WBC (Decrease), Day 60 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - AST, Day 30 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - Hgb (Change from baseline), Day 60 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 60 | 33 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - CREA, Day 7 | 40 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - PLA, Day 60 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 2 - WBC (Decrease), Day 60 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - WBC (Increase), Day 60 | 29 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - AST, Day 30 | 3 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Normal - ALT, Day 0 | 37 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 0 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - PLA, Day 60 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Decrease), Day 60 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - Hgb (Decrease), Day 60 | 10 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - WBC (Increase), Day 37 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Missing - ALT, Day 7 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects Presenting Different Grades of Haematological and Biochemical Values | Grade 1 - CREA, Day 7 | 0 Participants |
Secondary
Number of Subjects With Any Solicited General Symptoms
Solicited general symptoms assessed were fatigue, gastrointestinal symptoms (Gastro), headache, malaise, myalgia and temperature. Any = occurrence of the symptom regardless of intensity grade.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available and who had filled in their symptom sheets.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Malaise, Dose 1 | 2 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Myalgia, Across doses | 4 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Temperature, Dose 1 | 0 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Myalgia, Dose 1 | 4 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Malaise, Across doses | 2 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Headache, Across doses | 4 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Gastro, Dose 1 | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Temperature, Across doses | 5 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Gastro, Across doses | 2 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Fatigue, Across doses | 2 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Temperature, Dose 2 | 5 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Myalgia, Dose 2 | 3 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Headache, Dose 1 | 2 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Fatigue, Dose 1 | 2 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Malaise, Dose 2 | 2 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Headache, Dose 2 | 4 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Gastro, Dose 2 | 1 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Fatigue, Dose 2 | 2 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Headache, Dose 1 | 3 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Fatigue, Dose 1 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Gastro, Dose 1 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Malaise, Dose 1 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Myalgia, Dose 1 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Temperature, Dose 1 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Fatigue, Dose 2 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Gastro, Dose 2 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Headache, Dose 2 | 2 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Malaise, Dose 2 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Myalgia, Dose 2 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Temperature, Dose 2 | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Fatigue, Across doses | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Gastro, Across doses | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Headache, Across doses | 3 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Malaise, Across doses | 2 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Myalgia, Across doses | 0 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Temperature, Across doses | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Headache, Dose 1 | 3 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Malaise, Dose 1 | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Malaise, Dose 2 | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Myalgia, Dose 1 | 2 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Fatigue, Dose 1 | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Temperature, Dose 2 | 4 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Myalgia, Dose 2 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Malaise, Across doses | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Gastro, Dose 2 | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Headache, Across doses | 4 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Temperature, Across doses | 6 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Gastro, Across doses | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Fatigue, Dose 2 | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Myalgia, Across doses | 2 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Headache, Dose 2 | 2 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Temperature, Dose 1 | 2 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Gastro, Dose 1 | 1 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Fatigue, Across doses | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Gastro, Dose 2 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Fatigue, Dose 1 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Fatigue, Dose 2 | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Headache, Dose 1 | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Headache, Dose 2 | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Myalgia, Across doses | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Malaise, Dose 2 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Myalgia, Dose 2 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Temperature, Dose 2 | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Gastro, Dose 1 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Fatigue, Across doses | 1 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Gastro, Across doses | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Headache, Across doses | 2 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Temperature, Across doses | 3 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Malaise, Across doses | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Malaise, Dose 1 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Myalgia, Dose 1 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Temperature, Dose 1 | 2 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Temperature, Dose 1 | 3 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Malaise, Dose 2 | 1 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Myalgia, Dose 1 | 3 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Fatigue, Across doses | 2 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Headache, Dose 2 | 8 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Gastro, Across doses | 2 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Gastro, Dose 2 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Headache, Across doses | 8 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Fatigue, Dose 1 | 2 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Temperature, Across doses | 9 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Fatigue, Dose 2 | 1 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Malaise, Dose 1 | 2 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Myalgia, Across doses | 3 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Malaise, Across doses | 2 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Myalgia, Dose 2 | 3 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Gastro, Dose 1 | 2 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Headache, Dose 1 | 4 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited General Symptoms | Any Temperature, Dose 2 | 9 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Gastro, Dose 1 | 1 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Malaise, Across doses | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Headache, Dose 2 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Myalgia, Across doses | 1 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Malaise, Dose 2 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Fatigue, Across doses | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Myalgia, Dose 2 | 1 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Temperature, Across doses | 1 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Gastro, Dose 2 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Myalgia, Dose 1 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Malaise, Dose 1 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Gastro, Across doses | 1 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Fatigue, Dose 1 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Temperature, Dose 1 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Headache, Dose 1 | 2 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Fatigue, Dose 2 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Temperature, Dose 2 | 1 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited General Symptoms | Any Headache, Across doses | 2 Participants |
Secondary
Number of Subjects With Any Solicited Local Symptoms
Solicited local symptoms assessed were pain and swelling. Any = occurrence of the symptom regardless of intensity grade.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available and who had filled in their symptom sheets.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited Local Symptoms | Any Swelling, Across doses | 5 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited Local Symptoms | Any Pain, Dose 2 | 10 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited Local Symptoms | Any Pain, Across doses | 14 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited Local Symptoms | Any Pain, Dose 1 | 12 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited Local Symptoms | Any Swelling, Dose 1 | 3 Participants |
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Solicited Local Symptoms | Any Swelling, Dose 2 | 4 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited Local Symptoms | Any Swelling, Across doses | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited Local Symptoms | Any Pain, Dose 1 | 7 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited Local Symptoms | Any Pain, Dose 2 | 5 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited Local Symptoms | Any Pain, Across doses | 7 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited Local Symptoms | Any Swelling, Dose 1 | 1 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Solicited Local Symptoms | Any Swelling, Dose 2 | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited Local Symptoms | Any Pain, Dose 2 | 5 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited Local Symptoms | Any Swelling, Across doses | 4 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited Local Symptoms | Any Swelling, Dose 1 | 2 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited Local Symptoms | Any Pain, Dose 1 | 6 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited Local Symptoms | Any Swelling, Dose 2 | 2 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Solicited Local Symptoms | Any Pain, Across doses | 8 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited Local Symptoms | Any Pain, Dose 1 | 3 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited Local Symptoms | Any Pain, Across doses | 3 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited Local Symptoms | Any Swelling, Across doses | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited Local Symptoms | Any Swelling, Dose 2 | 0 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited Local Symptoms | Any Pain, Dose 2 | 2 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Solicited Local Symptoms | Any Swelling, Dose 1 | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited Local Symptoms | Any Pain, Dose 2 | 7 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited Local Symptoms | Any Pain, Dose 1 | 8 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited Local Symptoms | Any Swelling, Dose 2 | 4 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited Local Symptoms | Any Swelling, Across doses | 4 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited Local Symptoms | Any Swelling, Dose 1 | 2 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Solicited Local Symptoms | Any Pain, Across doses | 9 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited Local Symptoms | Any Swelling, Across doses | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited Local Symptoms | Any Pain, Dose 1 | 3 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited Local Symptoms | Any Swelling, Dose 1 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited Local Symptoms | Any Pain, Dose 2 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited Local Symptoms | Any Swelling, Dose 2 | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Solicited Local Symptoms | Any Pain, Across doses | 3 Participants |
Secondary
Number of Subjects With Any Unsolicited AEs
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: During the 30-day (Days 0-29) post-vaccination period
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HIV(+)-HA/GSK692342 | Number of Subjects With Any Unsolicited AEs | 26 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With Any Unsolicited AEs | 27 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With Any Unsolicited AEs | 35 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With Any Unsolicited AEs | 33 Participants |
| HIV(-)/GSK692342 | Number of Subjects With Any Unsolicited AEs | 13 Participants |
| HIV(-)/Placebo | Number of Subjects With Any Unsolicited AEs | 13 Participants |
Secondary
Number of Subjects With SAEs
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From one month post Dose 2 up to study end (Year 3)
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HIV(+)-HA/GSK692342 | Number of Subjects With SAEs | 2 Participants |
| HIV(+)-HA/Placebo | Number of Subjects With SAEs | 0 Participants |
| HIV(+)-TN/ GSK692342 | Number of Subjects With SAEs | 2 Participants |
| HIV(+)-TN/Placebo | Number of Subjects With SAEs | 0 Participants |
| HIV(-)/GSK692342 | Number of Subjects With SAEs | 0 Participants |
| HIV(-)/Placebo | Number of Subjects With SAEs | 0 Participants |